香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購浦發銀行結構性存款產品 認購結構性存款產品 近日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議，同意以日常營運產生的自有閑置資 金向浦發銀行認購總金額為人民幣 2.20 億元的結構性存款產品。 上市規則的涵義 | 觀察價格區間 | 實際年化收益率 | | --- | --- | | 觀察價格＜期初價格*91.00% | 0.85% | | 期初價格*91.00%≤觀察價格＜期初價格*106.05% | 2.20% | | 觀察價格≥期初價格*106.05% | 2.40% | 其中：期初價格為二零二五年四月二日北京時間 14 點於彭博 BFIX 頁面公佈 的歐元兌美元定盤價；觀察價格為二零二五年六月二十五日北京時間 14點於 彭博 BFIX 頁面公佈的歐元兌美元定盤價。 終止及贖回： 该協議按約定期限履行，本公司無權提前終止或贖回。浦發銀行可出於不可 抗力或投資公眾的利益提早終止。 - ...

Group 1 - CIMC reported a net profit of RMB 29.72 billion for 2024, a year-on-year increase of 605.60% [1] - CIMC's revenue reached RMB 1,776.64 billion, up 39.01% from the previous year [1] - The container manufacturing segment generated revenue of RMB 622.05 billion, a 105.89% increase year-on-year [1] Group 2 - CIMC Vehicles reported revenue of RMB 209.98 billion, a decrease of 16.30% year-on-year [2] - Net profit for CIMC Vehicles fell to RMB 10.81 billion, down 55.83% compared to the previous year [2] - The decline in net profit was attributed to normalization of North American business and non-recurring gains from a previous equity disposal [2] Group 3 - SMIC's revenue for 2024 was RMB 57,795.6 million, an increase of 27.7% year-on-year [3] - The net profit for SMIC decreased by 23.3% to RMB 3,698.7 million [3] - The increase in revenue was driven by a rise in wafer sales volume, which increased by 36.7% [3] Group 4 - Haier Smart Home achieved a net profit of RMB 187.41 billion, a year-on-year increase of 12.92% [4] - The company reported revenue of RMB 2,859.81 billion, up 4.29% from the previous year [4] - The gross margin for Haier Smart Home was 27.8%, an increase of 0.3 percentage points from 2023 [4] Group 5 - CNOOC reported a net profit of RMB 137.94 billion for 2024, an increase of 11.4% year-on-year [6] - The company's revenue was RMB 420.51 billion, a slight increase of 0.9% from the previous year [6] - CNOOC's oil and gas production reached 199 million barrels of oil equivalent per day [6] Group 6 - CNOOC's oil liquid sales volume increased by 9.4% to 562.9 million barrels [7] - The average realized oil price was USD 76.75 per barrel, a decrease of approximately 1.6% [7] - The company achieved a reserve replacement rate of 167% with 11 new discoveries [7] Group 7 - China Merchants Securities reported a net profit of RMB 103.86 billion, an increase of 18.51% year-on-year [8] - The company achieved revenue of RMB 208.91 billion for the year [8] - Wealth management and institutional business contributed RMB 102.33 billion to the revenue [8] Group 8 - China Merchants Energy reported a net profit of RMB 51.07 billion for 2024 [9] - The company's revenue was RMB 257.99 billion, with a slight decrease of 0.32% [9] - The revenue decline was influenced by fluctuations in the oil tanker market [9] Group 9 - Industrial Bank achieved a net profit of RMB 772.05 billion, a year-on-year increase of 0.12% [11] - The bank's revenue was RMB 2,122.26 billion, up 0.66% from the previous year [11] - The non-performing loan ratio was 1.07%, indicating stable asset quality [11] Group 10 - Weichai Power reported a net profit of RMB 114.03 billion, a year-on-year increase of 26.51% [12] - The company's revenue reached RMB 2,156.9 billion, up 0.81% [12] - The sales of various engines totaled 734,000 units, with a 5% increase in exports [13] Group 11 - Lens Technology achieved a net profit of RMB 36.24 billion, a year-on-year increase of 19.94% [14] - The company reported revenue of RMB 698.97 billion, up 28.27% [14] - The smartphone and computer segments contributed significantly to revenue growth [14] Group 12 - Shandong Gold reported a net profit of RMB 29.52 billion, a year-on-year increase of 26.80% [15] - The company's revenue was RMB 825.18 billion, up 39.21% [15] Group 13 - Huadian International achieved a net profit of RMB 57.03 billion, a year-on-year increase of 26.11% [16] - The company's revenue was RMB 1,129.94 billion, a decrease of 3.57% [16] Group 14 - Postal Savings Bank reported a revenue of RMB 348.77 billion, a year-on-year increase of 1.83% [16] - The bank's net interest income was RMB 286.12 billion, up 1.53% [16] Group 15 - Joyoung reported a net profit of RMB 1.22 billion, a year-on-year decrease of 68.55% [17] - The company's revenue was RMB 8.85 billion, down 7.94% [17] Group 16 - Shanghai Pharmaceuticals achieved a net profit of RMB 45.53 billion, a year-on-year increase of 20.82% [18] - The company's revenue was RMB 2,752.51 billion, up 5.75% [18] Group 17 - CITIC Securities reported a net profit of RMB 72.23 billion, a year-on-year increase of 2.68% [19] - The company's revenue was RMB 211.29 billion, down 9.1% [19] Group 18 - Three squirrels plan to issue H-shares and apply for listing on the Hong Kong Stock Exchange [21] - The company aims to enhance global brand recognition and expand overseas financing capabilities [21] Group 19 - CIMC announced the termination of the spin-off of its subsidiary CIMC Tianda for listing on the Shenzhen Stock Exchange [22] - The decision was made for comprehensive considerations regarding business development and capital operation planning [22] Group 20 - CNOOC's subsidiary CIMC Tianda withdrew its IPO application [23] - The expected fundraising amount was RMB 1.41941 billion [23]

上海复旦张江生物医药股份有限公司 (除特别注明外，金额单位为人民币元) 一 公司的基本情况 上海复旦张江生物医药股份有限公司(原名：上海复旦张江生物医药有限公 司，以下简称"本公司")于 1996 年 11 月 11 日在中华人民共和国成立，初 始注册资本及实收资本为 5,295,000 元。 于 2000 年 10 月 20 日，经过历次增资及股权变动，本公司的注册资本及实 收资本由 5,295,000 元增加至 53,000,000 元。 本公司于 2000 年 11 月 8 日改制为股份有限公司，改制完成后更名为上海复 旦张江生物医药股份有限公司，本公司的注册资本及股本为 53,000,000 元， 分为 53,000,000 股人民币普通股，每股面值 1 元。 于 2002 年 1 月 20 日，本公司将每股面值为 1 元的 53,000,000 股人民币普 通股拆细为每股面值 0.10 元的 530,000,000 股人民币普通股("内资股")。 于 2002 年 8 月 13 日，本公司发行了 198,000,000 股面值为 0.10 元境外普 通 股 ( 以下简称 "H 股" ) ，其中 18 ...

股票代码：688505 股票简称：复旦张江 编号：临 2025-011 上海复旦张江生物医药股份有限公司 关于提请股东大会授权董事会以简易程序向特定对象 发行股票的公告 本次提请股东大会授权事宜包括以下内容： （一）确认公司是否符合以简易程序向特定对象发行股票条件 提请股东大会授权董事会根据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司证券发行注册管理办法》《香港联合交易所有限公司证券上 市规则》等有关法律法规和规范性文件的规定，对公司实际情况进行自查和论证， 确认公司是否符合以简易程序向特定对象发行股票条件。 （二）发行股票的种类、面值 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《上海证券交易所上市公司证券发行与承销业务实施细则》及 《香港联合交易所有限公司证券上市规则》（包括第 13.36 条及 19A.38 条）等 相关规定，上海复旦张江生物医药股份有限公司（以下简称"公司"）于 2025 年 ...

上海复旦张江生物医药股份有限公司 作为上海复旦张江生物医药股份有限公司（以下简称"公司""本公司"）董事 会独立非执行董事（亦称"独立董事"），本人严格按照《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上海证券交易所科创板股票上市规则》《香港联合交易所有限公司证券上市规 则》等法律、法规、规范性文件及《公司章程》的要求，于 2024 年度任职期间 即 2024 年 1 月 1 日至 2024 年 12 月 31 日期间（以下简称"报告期内"），积极参 加公司董事会及各专门委员会会议，认真审议各项议案，切实履行了独立董事的 职责和义务，审慎行使了公司和股东所赋予的权利，维护了全体股东的合法利益， 充分发挥独立董事的作用。现将本人 2024 年度履职情况报告如下： 一、 独立董事的基本情况 （一）本人的工作履历、专业背景及兼职情况如下 王宏广先生，1962 年出生，于二零二三年五月三十日获委任为公司独立非 执行董事。现任四川大学华西医院中国人民生命安全研究院院长。曾任中国农业 大学副教授、教授；科学技术部农村与社会发展司副司长；科学技术部中国生物 技术发展中 ...

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 709,405,000, a decrease of 16.6% compared to RMB 850,733,000 in 2023[3] - Profit before tax for 2024 was RMB 5,458,000, down 94.4% from RMB 97,528,000 in 2023[3] - Net profit attributable to shareholders for 2024 was RMB 39,734,000, a decline of 63.4% from RMB 108,627,000 in 2023[3] - The company reported a basic and diluted earnings per share of RMB 0.0383 for 2024, down 63.5% from RMB 0.1051 in 2023[3] - The company’s total comprehensive income for 2024 was RMB 39,745,000, compared to RMB 107,793,000 in 2023, a decrease of 63.1%[3] - Net profit for 2024 was RMB 39,434,072, down 63.6% from RMB 108,449,858 in 2023[9] - The company reported a net profit attributable to shareholders of RMB 39,733,896 for 2024, down from RMB 108,627,368 in 2023, representing a decrease of approximately 63.4%[176] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 2,586,503,000, a decrease of 10.1% from RMB 2,876,688,000 in 2023[4] - Total liabilities decreased to RMB 281,226,000 in 2024 from RMB 518,124,000 in 2023, representing a reduction of 45.4%[6] - Total liabilities decreased significantly to RMB 217,064,267 in 2024, down 52.3% from RMB 450,634,658 in 2023[8] - Total equity decreased to RMB 2,273,482,301 in 2024, a decline of 4.4% from RMB 2,379,229,295 in 2023[8] - The company’s current liabilities totaled RMB 202,636,602 in 2024, a decrease of 53.8% from RMB 439,267,111 in 2023[8] Cash Flow - Consolidated operating cash flow for 2024 was a net outflow of RMB 16,512,634, compared to a net inflow of RMB 71,015,450 in 2023, representing a significant decline[12] - The ending cash balance for 2024 was RMB 1,056,285,629, down from RMB 1,195,895,997 in 2023, representing a decrease of about 11.7%[12] - Operating cash inflow for the company was RMB 686,316,914 in 2024, a decline from RMB 787,256,011 in 2023, indicating a decrease of approximately 12.8%[13] - The company experienced a net cash outflow from operating activities of RMB 48,970,056 in 2024, compared to a net inflow of RMB 10,422,159 in 2023[13] - The company’s net cash decrease for 2024 was RMB 123,954,045, compared to RMB 120,474,705 in 2023, indicating a slight increase in cash outflow[13] Research and Development - Research and development expenses increased to RMB 314,162,142 in 2024, up 29% from RMB 243,762,975 in 2023[9] - Total R&D expenditure for 2024 amounted to RMB 314,162,142, an increase from RMB 244,700,356 in 2023, representing a growth of approximately 28.3%[151] - Outsourced R&D costs in 2024 were RMB 122,046,365, compared to RMB 94,265,372 in 2023, reflecting a year-over-year increase of about 29.5%[151] Inventory and Impairment - The company’s inventory increased to RMB 47,265,443 in 2024 from RMB 43,651,360 in 2023, an increase of 3.5%[5] - The inventory value as of December 31, 2024, was RMB 47,837,018, with a provision for inventory impairment of RMB 571,575, compared to RMB 44,368,610 and RMB 717,250 respectively in 2023[126] - The company reported a significant reduction in inventory impairment provisions for finished goods, decreasing from RMB 662,517 in 2023 to RMB 111,476 in 2024[127] - The inventory write-down provision decreased to RMB 571,575 in 2024 from RMB 717,250 in 2023, showing a reduction of about 20.3%[158] Dividends and Retained Earnings - The company distributed dividends amounting to RMB 93,291,489 to shareholders during 2024, which contributed to the decrease in retained earnings[15] - The company declared a cash dividend of RMB 0.07 per share for the 2023 fiscal year, totaling RMB 72,560,047 based on 1,036,572,100 shares issued[176] - The company plans to distribute a cash dividend of RMB 0.02 per share for the first half of 2024, amounting to RMB 20,731,442[176] Government Grants and Subsidies - Government grants are recognized when conditions are met, measured at the amount received or receivable, and can be related to assets or income[77] - Government subsidies received amounted to RMB 19,397,448 in 2024, a decrease from RMB 25,580,068 in 2023[186] - The company received government subsidies amounting to CNY 29,144,056 in 2024, an increase from CNY 23,197,893 in 2023[194] Financial Instruments and Investments - The company recognizes expected credit losses based on historical experience and current conditions, applying a three-stage model for credit risk assessment[39] - The company reported a loss of RMB 7,974,882 from its investment in Shanghai Handoo Pharmaceutical Technology Co., Ltd. for the year 2024[141] - The total long-term equity investments as of December 31, 2024, were RMB 257,482,937, down from RMB 287,518,193 in 2023, indicating a decrease of 10.4%[133] Accounting Policies and Compliance - The company’s financial statements are prepared in accordance with the Chinese accounting standards, ensuring compliance and transparency in financial reporting[22] - The financial statements for the year 2024 are prepared based on the going concern assumption, reflecting the consolidated and company financial position as of December 31, 2024[23] - The company has adopted the new accounting standards (Interpretation No. 17 and No. 18) issued in 2023 and 2024, which did not have a significant impact on its financial statements[93]

第八届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海复旦张江生物医药股份有限公司（以下简称"公司"或"本公司"）第八届 监事会第八次会议于 2025 年 3 月 13 日以书面方式发出会议通知，于 2025 年 3 月 27 日以现场表决方式召开，由公司监事会主席黄建先生召集，会议应参加表 决监事 3 人，实际参加表决监事 3 人，本次会议的召集、召开符合《中华人民共 和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称 "《证券法》"）等法律、法规和《上海复旦张江生物医药股份有限公司章程》（以 下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 经与会监事审议，做出如下决议： 股票代码：688505 股票简称：复旦张江 编号：临2025-007 上海复旦张江生物医药股份有限公司 （一）审议通过《关于 2024 年度财务决算报告的议案》 经审议，公司监事会认为公司编制的 2024 年度财务决算报告如实反映了报 告期内的财务状况、经营成果。 ...

股票代码：688505 股票简称：复旦张江 编号：临2025-006 表决情况：7 票同意，0 票反对，0 票弃权。 上海复旦张江生物医药股份有限公司 第八届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海复旦张江生物医药股份有限公司（以下简称"公司"或"本公司"）第八届 董事会第九次会议于 2025 年 3 月 13 日以书面方式发出会议通知，于 2025 年 3 月 27 日以现场结合通讯表决方式召开，由公司董事会主席赵大君先生召集，会 议应出席的董事 7 人，实际出席的董事 7 人，其中独立董事 3 人，公司全体监事 和董事会秘书列席了会议。本次会议的通知和召开符合《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上 海证券交易所科创板股票上市规则》和《公司章程》的规定。 二、董事会会议审议情况 经与会董事审议，做出如下决议： （一）审议通过《关于 2024 年度总经理工作报告的议案》 2024 年公司经营管理 ...

股票代码：688505 股票简称：复旦张江 编号：临 2025-008 上海复旦张江生物医药股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股派发现金红利人民币 0.03 元（含税）。公司本年度不进行转增，不送 红股； 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确； 在实施权益分派的股权登记日前，公司总股本发生变动的，拟维持每股 派发现金红利金额不变，相应调整分配的总额，并将另行公告具体调整情况； 不触及《上海证券交易所科创板股票上市规则》（以下简称《科创板股票 上市规则》）第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情 形。 一、利润分配方案内容 经普华永道中天会计师事务所（特殊普通合伙）审计，上海复旦张江生物医 药股份有限公司（以下简称"公司"）2024年度合并报表中归属于上市公司股东的 净利润为人民币39,733,896元。截至2024年12月31日，母公司累计未分配利润为 人 ...

股票代码：688505 股票简称：复旦张江 编号：临 2025-011 上海复旦张江生物医药股份有限公司 关于提请股东大会授权董事会以简易程序向特定对象 发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《上海证券交易所上市公司证券发行与承销业务实施细则》及 《香港联合交易所有限公司证券上市规则》（包括第 13.36 条及 19A.38 条）等 相关规定，上海复旦张江生物医药股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开第八届董事会第九次会议，审议通过《关于提请股东大会授权董 事会办理以简易程序向特定对象发行股票相关事宜的议案》，董事会将获授权决 定公司向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资 产 20%的股票，授权期限(i)自公司 2024 年度股东周年大会审议通过之日起至公 司 2025 年度股东周年大会召开之日；(ii)自公司 2024 年度股东周年 ...